How Ebola Stocks Are Responding After the Outbreak in the Congo

Photo of Chris Lange
By Chris Lange Updated Published
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
How Ebola Stocks Are Responding After the Outbreak in the Congo

© Thinkstock

[cnxvideo id=”655426″ placement=”ros”]The World Health Organization (WHO) has confirmed a new outbreak of the Ebola virus in the Democratic Republic of Congo. So far at least one person has died after contracting the virus, in a lab-confirmed case. This is the first time in a while that the virus has resurfaced, and a few of the Ebola-related stocks are responding.

In the last major outbreak between 2014 and 2015, over 11,000 people died in West Africa, mainly in Guinea, Sierra Leone and Liberia.

24/7 Wall St. has taken a quick look at a few stocks that have an Ebola treatment in their portfolio or deal directly with the virus. We have included a recent trading history, as well as some color and the consensus analyst price target.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) saw its shares up 1.5% at $34.02, with a consensus analyst price target of $60.88 and a 52-week trading range of $14.83 to $63.73. Year to date, shares are up 22%.

[nativounit]

Lakeland Industries Inc. (NASDAQ: LAKE) shares are up over 8% at $11.94. The stock has a 52-week range of $8.00 to $11.95 and a consensus price target of $15.00. So far in 2017, excluding Friday’s move, the stock is up nearly 6%.

Novavax Inc. (NASDAQ: NVAX) shares are up 1% at $0.94, with a consensus price target of $3.48 and a 52-week range of $0.73 to $8.49. Year to date, the stock is down 26%.

NewLink Genetics Corp. (NASDAQ: NLNK) saw its stock jump 3.6% to $17.45, within a 52-week range of $9.41 to $25.17 and with a consensus price target of $26.80. In 2017, the stock is up 63%.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) shares are up nearly 1% at $90.16. The stock has a 52-week range of $73.45 to $102.49. Year to date, the stock is up about 8%.

[wallst_email_signup]

Photo of Chris Lange
About the Author Chris Lange →

Chris Lange is a writer for 24/7 Wall St., based in Houston. He has covered financial markets over the past decade with an emphasis on healthcare, tech, and IPOs. During this time, he has published thousands of articles with insightful analysis across these complex fields. Currently, Lange's focus is on military and geopolitical topics.

Lange's work has been quoted or mentioned in Forbes, The New York Times, Business Insider, USA Today, MSN, Yahoo, The Verge, Vice, The Intelligencer, Quartz, Nasdaq, The Motley Fool, Fox Business, International Business Times, The Street, Seeking Alpha, Barron’s, Benzinga, and many other major publications.

A graduate of Southwestern University in Georgetown, Texas, Lange majored in business with a particular focus on investments. He has previous experience in the banking industry and startups.

Continue Reading

Top Gaining Stocks

CBOE Vol: 1,568,143
PSKY Vol: 12,285,993
STX Vol: 7,378,346
ORCL Vol: 26,317,675
DDOG Vol: 6,247,779

Top Losing Stocks

LKQ
LKQ Vol: 4,367,433
CLX Vol: 13,260,523
SYK Vol: 4,519,455
MHK Vol: 1,859,865
AMGN Vol: 3,818,618